LON:TRX Tissue Regenix Group (TRX) Share Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free TRX Stock Alerts GBX 61.50 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range 61▼ 6250-Day Range 59.80▼ 68.7552-Week Range 48▼ 72.94Volume17,805 shsAverage Volume60,779 shsMarket Capitalization£43.40 millionP/E RatioN/ADividend Yield4.12%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsInsider TradesStock AnalysisChartCompetitorsInsider Trades Get Tissue Regenix Group alerts: Email Address Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About Tissue Regenix Group Stock (LON:TRX)Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth. In addition, the company offers DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, a decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it provides OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company offers DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks to optimise membrane defects; and sports medicine products. Tissue Regenix Group plc was incorporated in 2006 and is based in Garforth, the United Kingdom.Read More TRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRX Stock News HeadlinesApril 6, 2024 | finance.yahoo.comTissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?March 21, 2024 | finance.yahoo.comTissue Regenix unveils growth strategy and positive EBITDA milestoneJanuary 25, 2024 | lse.co.ukTissue Regenix Group Share ChatJanuary 25, 2024 | finance.yahoo.comInvestors in Tissue Regenix Group (LON:TRX) from five years ago are still down 90%, even after 16% gain this past weekNovember 23, 2023 | morningstar.comTissue Regenix Group PLC TRXSeptember 8, 2023 | finance.yahoo.comTissue Regenix Group First Half 2023 Earnings: US$0.013 loss per share (vs US$0.023 loss in 1H 2022)September 5, 2023 | finance.yahoo.comTissue Regenix Group says "disciplined approach" paying off at half-year stageApril 18, 2023 | finance.yahoo.comImproved Revenues Required Before Tissue Regenix Group plc (LON:TRX) Shares Find Their FeetMarch 15, 2023 | bbc.co.ukTissue by Imtiaz DharkerFebruary 2, 2023 | finance.yahoo.comTissue Regenix Group "has the opportunity to become a global commercial organisation"January 31, 2023 | proactiveinvestors.comTissue Regenix highlights 20%-plus revenue growth across all three of its key business segments in 2022January 18, 2023 | proactiveinvestors.comTissue Regenix strikes China distribution deal with Hong Kong-based groupJanuary 18, 2023 | proactiveinvestors.comTissue Regenix shares rise 7% after China deal; broker says Kingsung Medical tie-up is 'encouraging'January 10, 2023 | finance.yahoo.comWhen Will Tissue Regenix Group plc (LON:TRX) Breakeven?December 7, 2022 | proactiveinvestors.comTissue Regenix extends VNEW allograft range to support SUI treatmentsNovember 22, 2022 | proactiveinvestors.comTissue Regenix inks German distribution dealSeptember 27, 2022 | proactiveinvestors.comTissue Regenix on course for underlying profitability in Q4, says research houseSeptember 7, 2022 | proactiveinvestors.comTissue Regenix says recent growth 'is sustainable' after commercial reorganisationSeptember 7, 2022 | proactiveinvestors.comTissue Regenix says first-half losses narrow on sales growth, cost managementSeptember 7, 2022 | proactiveinvestors.comTissue Regenix says first-half losses narrow on sales growth, cost managementAugust 11, 2022 | uk.finance.yahoo.comHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correctAugust 3, 2022 | finance.yahoo.comWhen Will Tissue Regenix Group plc (LON:TRX) Become Profitable?July 25, 2022 | msn.comSMALL CAP IDEA: Tissue Regenix shows regeneration is the way to healthy growthJuly 21, 2022 | proactiveinvestors.comTissue Regenix: Four-pronged strategy delivers double-digit growthJuly 21, 2022 | proactiveinvestors.comTissue Regenix: Four-pronged strategy helping deliver on growth aspirationsSee More Headlines Receive TRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/02/2020Today5/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:TRX CUSIPN/A CIKN/A Webwww.tissueregenix.com Phone+44-1904-567609FaxN/AEmployees82Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.02) Trailing P/E RatioN/A Forward P/E Ratio113.28 P/E GrowthN/ANet Income£-1,710,000.00 Net Margins-5.81% Pretax MarginN/A Return on Equity-5.55% Return on Assets-0.55% Debt Debt-to-Equity Ratio32.01 Current Ratio4.03 Quick Ratio2.36 Sales & Book Value Annual Sales£29.49 million Price / Sales1.47 Cash FlowGBX 10.79 per share Price / Cash Flow5.70 Book ValueGBX 43 per share Price / Book1.43Miscellaneous Outstanding Shares70,570,000Free FloatN/AMarket Cap£43.40 million OptionableNot Optionable Beta1.46 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Daniel Ray Lee (Age 63)CEO & Director Comp: $498.95kMr. David Claiborne Cocke (Age 59)CFO & Executive Director Comp: $294.87kMs. Christine RowleyTechnical & Operations Director - UKTina TrimbleSenior Vice President, Donor Services - U.S.Ms. Kirsten Mary LundEMEA Business Director & Company SecretaryKey CompetitorsSareumLON:SARArecor TherapeuticsLON:ARECe-therapeuticsLON:ETXBiodexa PharmaceuticalsLON:MTPHCollagen Solutions plc (COS.L)LON:COSView All CompetitorsInsidersBrian PhillipsBought 6,773 shares on 9/15/2023Total: £365,742.00 ($54.00/share)View All Insider Transactions TRX Stock Analysis - Frequently Asked Questions How have TRX shares performed in 2024? Tissue Regenix Group's stock was trading at GBX 52 at the beginning of 2024. Since then, TRX stock has increased by 18.3% and is now trading at GBX 61.50. View the best growth stocks for 2024 here. How were Tissue Regenix Group's earnings last quarter? Tissue Regenix Group plc (LON:TRX) released its quarterly earnings data on Wednesday, September, 2nd. The company reported ($0.16) earnings per share for the quarter. Tissue Regenix Group had a negative trailing twelve-month return on equity of 5.55% and a negative net margin of 5.81%. What other stocks do shareholders of Tissue Regenix Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tissue Regenix Group investors own include Argos Therapeutics (ARGSQ), Swedbank AB (publ) (SWDBY), Trevena (TRVN), Allied Minds (ALM), ArQule (ARQL), Boeing (BA), CIRCOR International (CIR), WisdomTree Middle East Dividend Fund (GULF) and W.W. Grainger (GWW). How do I buy shares of Tissue Regenix Group? Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:TRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 Media[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tissue Regenix Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.